ImmunoPrecise Antibodies (IPA)
(Delayed Data from NSDQ)
$0.67 USD
+0.03 (4.69%)
Updated Sep 13, 2024 03:59 PM ET
After-Market: $0.65 -0.02 (-2.99%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth C Momentum D VGM
Income Statements
Fiscal Year end for ImmunoPrecise Antibodies Ltd falls in the month of April .
All items in Millions except EPS data.
4/30/24 | 4/30/23 | 4/30/22 | 4/30/21 | 4/30/20 | |
---|---|---|---|---|---|
Sales | 18 | 16 | 15 | 14 | NA |
Cost Of Goods | 9 | 7 | 7 | 5 | NA |
Gross Profit | 9 | 9 | 9 | 9 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 19 | 30 | 22 | 14 | 0 |
Income After Depreciation & Amortization | -10 | -21 | -13 | -5 | 0 |
Non-Operating Income | -11 | 1 | 1 | 1 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -21 | -21 | -13 | -5 | NA |
Income Taxes | -1 | -1 | 1 | 1 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -20 | -20 | -13 | -6 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -20 | -20 | -13 | -6 | NA |
Depreciation Footnote | 4/30/24 | 4/30/23 | 4/30/22 | 4/30/21 | 4/30/20 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -6 | -16 | -10 | -3 | 0 |
Depreciation & Amortization (Cash Flow) | 4 | 5 | 3 | 3 | NA |
Income After Depreciation & Amortization | -10 | -21 | -13 | -5 | 0 |
Earnings Per Share Data | 4/30/24 | 4/30/23 | 4/30/22 | 4/30/21 | 4/30/20 |
---|---|---|---|---|---|
Average Shares | 25.64 | 24.90 | 19.69 | 16.47 | NA |
Diluted EPS Before Non-Recurring Items | -0.78 | -0.81 | -0.67 | -0.34 | NA |
Diluted Net EPS (GAAP) | -0.79 | -0.80 | -0.68 | -0.34 | NA |
Fiscal Year end for ImmunoPrecise Antibodies Ltd falls in the month of April .
All items in Millions except EPS data.
7/31/24 | 4/30/24 | 1/31/24 | 10/31/23 | 7/31/23 | |
---|---|---|---|---|---|
Sales | NA | 4.76 | 4.60 | 4.53 | 4.26 |
Cost Of Goods | NA | 2.47 | 2.24 | 2.35 | 2.17 |
Gross Profit | NA | 2.29 | 2.37 | 2.17 | 2.09 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 4.90 | 4.83 | 4.39 | 5.22 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -2.61 | -2.46 | -2.22 | -3.13 |
Non-Operating Income | NA | -0.18 | -0.09 | 0.32 | 0.26 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -13.92 | -2.56 | -1.91 | -2.87 |
Income Taxes | NA | -0.57 | -0.38 | 0.02 | -0.20 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -13.35 | -2.18 | -1.93 | -2.67 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -13.35 | -2.18 | -1.93 | -2.67 |
Earnings Per Share Data | 7/31/24 | 4/30/24 | 1/31/24 | 10/31/23 | 7/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 25.64 | 25.80 | 25.05 | 25.05 |
Diluted EPS Before Non-Recurring Items | NA | -0.52 | -0.08 | -0.07 | -0.11 |
Diluted Net EPS (GAAP) | NA | -0.53 | -0.08 | -0.07 | -0.10 |